Loading...
Loading...
First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc.. Spoken Alpha tracks TRAX's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks TRAX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TRAX.
curl https://api.spokenalpha.com/v1/companies/TRAX| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $6.24 | $4.29 | +45.4% | +1.2% | +0.4% |
| Q4 FY2026 | $6.22 | $4.37 | +42.3% | -1.8% | -1.6% |
| Q3 FY2026 | $6.21 | $4.30 | +44.4% | +0.6% | +2.8% |
| Q2 FY2026 | $5.74 | $4.31 | +33.1% | -2.5% | -3.6% |
| Q1 FY2025 | $6.40 | $4.44 | +44.2% | -3.2% | -1.6% |
| Q4 FY2025 | $5.59 | $4.27 | +30.8% | +1.7% | +3.1% |
| Q3 FY2025 | $5.58 | $4.22 | +32.3% | +2.6% | +0.1% |
| Q2 FY2025 | $5.88 | $4.35 | +35.2% | +3.3% | +5.0% |
| Q1 FY2024 | $6.33 | $4.46 | +42.0% | -2.3% | -4.8% |
| Q4 FY2024 | $6.25 | $4.55 | +37.4% | +2.2% | -0.5% |